Novartis was expecting a lot from its PARAGON-HF trial of Entresto in heart failure with preserved ejection fraction (HFpEF) and isn’t letting a missed endpoint scupper the programme.

In the phase III trial, which was stopped early, Entresto proved superior to the ACE inhibitor enalapril, reducing the risk of cardiovascular death or heart failure hospitalisation by 20 per cent ...

In its continued bid to waylay the launch of MSN Pharmaceuticals’ proposed Entresto generic, Novartis has told a federal ...

MSN Laboratories Pvt. Ltd. accused Novartis AG of trying to to strong-arm a Delaware judge into ruling on its bid to block MSN’s copy of the heart-disease drug Entresto before a July 15 pediatric ...

If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

Carrie Madormo, RN, MPH, is a health writer. She has over a decade of experience as a registered nurse, practicing in a variety of fields, such as pediatrics, oncology, chronic pain, and public ...

Among the report's highlights: 182 clinical trials are underway at 2,227 sites throughout North America and 2,302 in the rest of the world. This includes a notable increase in Phase I trials—48 ...

Randomized controlled trials are clinical trials in which at least two interventions — the test treatment and a control treatment — are simultaneously evaluated in two or more arms of the ...

The United States Olympic team trials for swimming will be returning to a familiar setting in 2028.On Wednesday, USA Swimming and Indiana Sports Corp announced the 2028 swimming trials will be ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases ...

Gonzales et al. conducted an open-label phase 1 clinical trial of rapamycin for mild cognitive impairment and dementia due to Alzheimer’s disease. Rapamycin is not detected in cerebrospinal ...